Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
July 22, 2025Current Problems in CardiologyOpen Access

Tafamidis: A game changer in transthyretin cardiomyopathy? A systematic review and meta-analysis of safety and efficacy

View Full Paper
Ask AI
Bookmark
Share

Authors

BHBilal HussainSDSanchit DuhanBPBansari Patel

Discussion

Loading...

Member takes

Overview

Systematic review shows tafamidis reduces mortality and hospitalizations in ATTR-CM, suggesting significant benefits for patients.

Key Points

  • Tafamidis significantly lowers all-cause mortality in patients with transthyretin cardiomyopathy, showing an odds ratio of 0.55 (p<0.0001).
  • The treatment is associated with decreased incidence of chronic heart failure exacerbations, evidenced by an odds ratio of 0.71 (p=0.04).
  • Seven studies were analyzed, employing the mantel-Haenszel method for binary outcomes and Hedges' g for continuous data.
  • Findings support tafamidis as a valuable treatment option for patients with ATTR-CM, emphasizing its efficacy in clinical practice.

Cite This Study

Hussain et al. (2025) studied this question.

synapsesocial.com/papers/689a061be6551bb0af8cd8afhttps://doi.org/10.1016/j.cpcardiol.2025.103129
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Cardiovascular-Related Mortality and Hospitalizations in Patients with Transthyretin Amyloid Cardiomyopathy Treated with Tafamidis: A Post Hoc Analysis of the Phase 3 ATTR-ACT and Long-Term Extension2026
  2. 2Safety and Efficacy of Tafamidis in Chinese Patients with Transthyretin Amyloid Cardiomyopathy2025
  3. 3Tafamidis treatment significantly reduces the risk of recurrent cardiovascular-related hospitalisation in patients with early stage transthyretin amyloid cardiomyopathy2025
  4. 4Contemporary Real-World Treatment of Cardiac Transthyretin Amyloidosis with Tafamidis: A Long-Term Multicentre Study2026
  5. 5Annual Cardiovascular-Related Hospitalization Days Avoided with Tafamidis in Patients with Transthyretin Amyloid Cardiomyopathy2022 · 15 citations